Johnson & Johnson pauses COVID vaccine trial as participant becomes ill | Inquirer ºÚÁÏÉç

ºÚÁÏÉç

Johnson & Johnson pauses COVID vaccine trial as participant becomes ill

/ 09:40 AM October 13, 2020

COVID-19, vaccine

FILE PHOTO: Small bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration

WASHINGTON — Johnson & Johnson said Monday it had temporarily halted its Covid-19 vaccine trial because one of its participants had become sick.

“We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant,” the company said in a statement.

Article continues after this advertisement

The pause means the online enrollment system has been closed for the 60,000-patient clinical trial while the independent patient safety committee is convened.

FEATURED STORIES
JPV

RELATED STORY:

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

sports
business
business
globalnation
sports
www
business
www
entertainment
globalnation
TAGS: Coronavirus, COVID-19, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 ºÚÁÏÉç | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.